CST6 suppresses osteolytic bone disease in multiple myeloma by blocking osteoclast differentiation

Osteolytic bone disease is a hallmark of multiple myeloma (MM). A significant fraction (~20%) of MM patients do not develop osteolytic lesions (OLs). The molecular basis for the absence of bone disease in MM is not understood. We combined PET-CT and gene expression profiling (GEP) of purified BM CD1...

Descripción completa

Detalles Bibliográficos
Autores principales: Gai, Dongzheng, Chen, Jin-Ran, Stewart, James P., Nookaew, Intawat, Habelhah, Hasem, Ashby, Cody, Sun, Fumou, Cheng, Yan, Li, Can, Xu, Hongwei, Peng, Bailu, Garg, Tarun K., Schinke, Carolina, Thanendrarajan, Sharmilan, Zangari, Maurizio, Chen, Fangping, Barlogie, Bart, van Rhee, Frits, Tricot, Guido, Shaughnessy, John D., Zhan, Fenghuang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Clinical Investigation 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9479617/
https://www.ncbi.nlm.nih.gov/pubmed/35881476
http://dx.doi.org/10.1172/JCI159527

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9479617/
https://www.ncbi.nlm.nih.gov/pubmed/35881476
http://dx.doi.org/10.1172/JCI159527

Ejemplares similares